BioStock published an article on 3 November 2022 about Cyxone, which can be read in full below. Malmö-based Cyxone recently published its report for the third quarter, which testifies that the company is focusing on the phase IIb study...
Read MoreBioStock published an article on 12 October 2022 about Cyxone, which can be read in full below. October 12 is World Arthritis Day, which every year draws attention to people living with arthritic diseases. This term refers to a...
Read MoreBioStock published an article on 22 September 2022 about Cyxone, which can be read in full below. At the beginning of the autumn, First North-listed Cyxone announced the recruitment of Erika Samuelsson as the new Chief Development Officer with...
Read MoreBioStock published an article on 31 August 2022 about Cyxone, which can be read in full below. Biopharmaceutical company Cyxone is fully focused on the upcoming phase IIb study with the candidate Rabeximod in rheumatoid arthritis. In the company’s...
Read MoreBioStock published an article on 19 August 2022 about Cyxone, which can be read in full below. This week, the scientific journal Biomedicine & Pharmacotherapy published an article regarding T20K, Cyxone’s drug candidate in multiple sclerosis. Behind the article...
Read MoreBioStock published an article on 7 July 2022 about Cyxone, which can be read in full below. In June, biotech Cyxone announced a change of management – Carl-Magnus Högerkorp stepped up from his role as Chief Operating Officer to...
Read MoreBioStock published an article on 22 June 2022 about Cyxone, which can be read in full below. The board of Malmö-based company Cyxone recently announced a change in management. Carl-Magnus Högerkorp, Chief Operating Officer, steps in as acting CEO...
Read MoreBioStock published an article on 20 May 2022 about Cyxone, which can be read in full below. First North-listed Cyxone recently published its Q1 report, a period during which the company carried out a rights issue of 61 MSEK,...
Read MoreBioStock published an article on 5 May 2022 about the great need of new treatment options for RA patients. Following the FDA’s safety warnings, a shift is seen away from JAK inhibitors for the treatment of rheumatoid arthritis. The...
Read MoreBioStock published an article on 7 February 2022 about Cyxone, which can be read in full below. Biotech company Cyxone recently announced the next step in the T20K project, their drug candidate for multiple sclerosis. The company has signed...
Read More